Korean J Hematol.  2010 Dec;45(4):219-221. 10.5045/kjh.2010.45.4.219.

Mesenchymal stromal cells: new insight on their identity and potential role in cell therapy

• Oh IH

• KMID: 2252029
• DOI: http://doi.org/10.5045/kjh.2010.45.4.219

Abstract

No abstract available.

MeSH Terms

Tissue Therapy

Figure

• 

  Fig. 1 New insights on the in vivo identity of MSCs. MSCs that show multi-potent differentiation in culture originate from pericytes (or skeletal stem cells; SSCs). These SSCs are cellular components in both the endosteal and perivascular niches as osteoblast or reticular cells adjacent to sinus endothelial cells (SECs) that interact with hematopoietic stem cells (HSCs) in the bone marrow. Thus, the in vivo identity of MSCs could be niche cells for tissue-specific stem cells.

Reference

1. Picinich SC, Mishra PJ, Mishra PJ, Glod J, Banerjee D. The therapeutic potential of mesenchymal stem cells. Cell- & tissue-based therapy. Expert Opin Biol Ther. 2007; 7:965–973. PMID: 17665987.

2. Caplan AI. Why are MSCs therapeutic? New data: new insight. J Pathol. 2009; 217:318–324. PMID: 19023885.

3. Oh IH, Kwon KR. Concise review: multiple niches for hematopoietic stem cell regulations. Stem Cells. 2010; 28:1243–1249. PMID: 20517982.

4. Oh IH. Microenvironmental targeting of Wnt/beta-catenin signals for hematopoietic stem cell regulation. Expert Opin Biol Ther. 2010; 10:1315–1329. PMID: 20636187.

5. Furlani D, Ugurlucan M, Ong L, et al. Is the intravascular administration of mesenchymal stem cells safe? Mesenchymal stem cells and intravital microscopy. Microvasc Res. 2009; 77:370–376. PMID: 19249320.